Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Liabilities: 2012-2024

Historic Other Non-Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 5 years, with Dec 2024 value amounting to $880,000.

  • Agios Pharmaceuticals' Other Non-Current Liabilities fell 92.21% to $90,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $90,000, marking a year-over-year decrease of 92.21%. This contributed to the annual value of $880,000 for FY2024, which is 23.88% down from last year.
  • As of FY2024, Agios Pharmaceuticals' Other Non-Current Liabilities stood at $880,000, which was down 23.88% from $1.2 million recorded in FY2023.
  • Agios Pharmaceuticals' Other Non-Current Liabilities' 5-year high stood at $3.3 million during FY2022, with a 5-year trough of $880,000 in FY2024.
  • For the 3-year period, Agios Pharmaceuticals' Other Non-Current Liabilities averaged around $1.8 million, with its median value being $1.2 million (2023).
  • Data for Agios Pharmaceuticals' Other Non-Current Liabilities shows a maximum YoY slumped of 64.75% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Agios Pharmaceuticals' Other Non-Current Liabilities stood at $3.3 million in 2022, then crashed by 64.75% to $1.2 million in 2023, then fell by 23.88% to $880,000 in 2024.